Skip to content

Study · Randomized controlled trial · n = 10 · 2001

8 results

Short-term estradiol supplementation augments growth hormone (GH) secretory responsiveness to dose-varying GH-releasing peptide infusions in healthy postmenopausal women.

Anderson SM, Shah N, Evans WS, Patrie JT, Bowers CY, Veldhuis JD

The Journal of clinical endocrinology and metabolism1 Feb 2001Cited by 60 (Europe PMC)

PMID11158008 (opens in a new tab)DOI10.1210/jcem.86.2.7240 (opens in a new tab)PepBankPUB-11158008
Publisher pagePubMedAsk about this study
Jump to 8 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study8

2 results from studies that gave the peptide. 2 results from people.

  1. 01HumanRandomized controlled trialPharmacokinetics

    In healthy postmenopausal women, GH half-life increased directly with the dose of GHRP‑2 (and the mean serum GH concentration) in both estradiol and placebo sessions.

    In plain wordsIn healthy postmenopausal women, higher GHRP‑2 doses went with a longer growth hormone half-life.

    Peptide
    GHRP-2
    Outcome
    IncreaseGH half-life by GHRP-2 dose
    Study

    n = 10

    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    0.03-3 microg/kg · intravenous bolusAs given in this study (human).

    Source sentences

    Summary
    GH half-life varied directly with dose of GHRP-2 (and, hence, the mean serum GH concentration) in both the E(2) and placebo sessions (test of zero slope hypothesis, P = 0.0018).
    2 context sentences
    Summary · context
    To examine this postulate, we studied 10 healthy estrogen-withdrawn postmenopausal women, who were given oral placebo or estrogen supplementation [1 mg micronized 17 beta-estradiol (E(2)) twice daily for 7-15 days] in a patient-blinded, prospective, randomized, and within-subject cross-over design.
    Summary · context
    The GH-releasing actions of five semilogarithmically increasing doses of GHRP-2 (absolute range, 0.03-3 microg/kg by bolus iv infusion) vs. saline were evaluated by frequent blood sampling on separate days in the morning while fasting.
  2. 02HumanRandomized controlled trialActivity measurement

    In healthy postmenopausal women, the deconvolved GH secretory burst peaked within 8-13 min of the intravenous GHRP‑2 bolus.

    In plain wordsIn healthy postmenopausal women, growth hormone release peaked within 8 to 13 minutes after a GHRP‑2 injection.

    Peptide
    GHRP-2
    Outcome
    Not applicableTime to GH secretory burst peak after GHRP-2 bolus
    Study

    n = 10

    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    0.03-3 microg/kg · intravenous bolusAs given in this study (human).

    Measurements

    Time to GH burst peak
    8 to 13 min
    after GHRP-2 bolus

    Source sentences

    Summary
    The deconvolved GH secretory burst peaked within 8-13 min of the bolus iv injection of GHRP-2, and this latency was not altered by E(2).
    2 context sentences
    Summary · context
    To examine this postulate, we studied 10 healthy estrogen-withdrawn postmenopausal women, who were given oral placebo or estrogen supplementation [1 mg micronized 17 beta-estradiol (E(2)) twice daily for 7-15 days] in a patient-blinded, prospective, randomized, and within-subject cross-over design.
    Summary · context
    The GH-releasing actions of five semilogarithmically increasing doses of GHRP-2 (absolute range, 0.03-3 microg/kg by bolus iv infusion) vs. saline were evaluated by frequent blood sampling on separate days in the morning while fasting.

Studies that did not test the peptide alone6

In this study, GHRP-2 was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking GHRP-2.

  1. 03HumanNot a test of GHRP-2 aloneRandomized controlled trialEfficacy outcome

    In healthy postmenopausal women, estradiol exposure enhanced the efficacy of the highest GHRP‑2 dose (3 microg/kg) by 2.1-fold versus placebo.

    In plain wordsIn healthy postmenopausal women, estradiol made the growth hormone response to the highest GHRP‑2 dose about twice as large as with placebo.

    Peptide
    GHRP-2
    Outcome
    IncreaseGH secretory response to highest GHRP-2 dose with estradiol
    Study

    n = 10

    Comparator
    Placebo
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones

    Measurements

    Efficacy increase
    2.1 fold
    GHRP-2 3 microg/kg with estradiol

    Source sentences

    Summary
    E(2) exposure enhanced the efficacy of the highest GHRP-2 dose tested (3 microg/kg) by 2.1-fold (1.3- to 3.3-fold; P = 0.010).
    2 context sentences
    Summary · context
    To examine this postulate, we studied 10 healthy estrogen-withdrawn postmenopausal women, who were given oral placebo or estrogen supplementation [1 mg micronized 17 beta-estradiol (E(2)) twice daily for 7-15 days] in a patient-blinded, prospective, randomized, and within-subject cross-over design.
    Summary · context
    The GH-releasing actions of five semilogarithmically increasing doses of GHRP-2 (absolute range, 0.03-3 microg/kg by bolus iv infusion) vs. saline were evaluated by frequent blood sampling on separate days in the morning while fasting.

    In this study, GHRP-2 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking GHRP-2.

  2. 04HumanNot a test of GHRP-2 aloneRandomized controlled trialEfficacy outcome

    In healthy postmenopausal women, estradiol combined with the highest GHRP‑2 dose stimulated GH secretory burst mass by a total of 31-fold versus placebo and saline.

    In plain wordsIn healthy postmenopausal women, estradiol with the highest GHRP‑2 dose raised growth hormone release 31-fold compared with placebo and saline.

    Peptide
    GHRP-2
    Outcome
    IncreaseGH secretory burst mass with estradiol and highest GHRP-2 dose
    Study

    n = 10

    Comparator
    Placebo and saline
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones

    Measurements

    GH secretory burst mass increase
    31 fold
    estradiol + highest GHRP-2 dose

    Source sentences

    Summary
    Compared with the effect of placebo and saline, E(2) combined with the highest dose of GHRP-2 stimulated GH secretory burst mass by a total of 31-fold (24- to 41-fold; P < 0.001).
    2 context sentences
    Summary · context
    To examine this postulate, we studied 10 healthy estrogen-withdrawn postmenopausal women, who were given oral placebo or estrogen supplementation [1 mg micronized 17 beta-estradiol (E(2)) twice daily for 7-15 days] in a patient-blinded, prospective, randomized, and within-subject cross-over design.
    Summary · context
    The GH-releasing actions of five semilogarithmically increasing doses of GHRP-2 (absolute range, 0.03-3 microg/kg by bolus iv infusion) vs. saline were evaluated by frequent blood sampling on separate days in the morning while fasting.

    In this study, GHRP-2 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking GHRP-2.

  3. 05HumanNot a test of GHRP-2 aloneRandomized controlled trialEfficacy outcome

    In healthy postmenopausal women, estradiol significantly augmented the amount of GH secreted per unit GHRP‑2 dose versus placebo (slope 16.6 versus 10.1).

    In plain wordsIn healthy postmenopausal women, estradiol increased how much growth hormone was released for each unit of GHRP‑2 compared with placebo.

    Peptide
    GHRP-2
    Outcome
    IncreaseGH secreted per unit GHRP-2 dose (regression slope) with estradiol
    Study

    n = 10

    Comparator
    Placebo
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones

    Measurements

    Dose-response slope
    16.6 slope units
    estradiol
    Dose-response slope
    10.1 slope units
    placebo

    Source sentences

    Summary
    Random coefficient regression analysis of the relationship between the logarithm of GHRP-2 dose and GH secretory burst mass revealed that E(2) significantly augmented the amount of GH secreted per unit GHRP-2 dose (E(2), 16.6 +/- 1.8 slope units; placebo, 10.1 +/- 1.4 slope units; P = 0.03).
    2 context sentences
    Summary · context
    To examine this postulate, we studied 10 healthy estrogen-withdrawn postmenopausal women, who were given oral placebo or estrogen supplementation [1 mg micronized 17 beta-estradiol (E(2)) twice daily for 7-15 days] in a patient-blinded, prospective, randomized, and within-subject cross-over design.
    Summary · context
    The GH-releasing actions of five semilogarithmically increasing doses of GHRP-2 (absolute range, 0.03-3 microg/kg by bolus iv infusion) vs. saline were evaluated by frequent blood sampling on separate days in the morning while fasting.

    In this study, GHRP-2 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking GHRP-2.

  4. 06HumanNot a test of GHRP-2 aloneRandomized controlled trialPharmacokinetics

    In healthy postmenopausal women, the mean endogenous GH half-life did not differ between estradiol and placebo sessions (18 versus 17 min).

    In plain wordsIn healthy postmenopausal women, estradiol did not change how long growth hormone stayed in the blood compared with placebo.

    Peptide
    GHRP-2
    Outcome
    No significant changeEndogenous GH half-life with estradiol versus placebo
    Study

    n = 10

    Comparator
    Placebo
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones

    Measurements

    GH half-life
    18 min
    estradiol
    GH half-life
    17 min
    placebo

    Source sentences

    Summary
    Although the global mean endogenous GH half-life did not differ between the E(2) and placebo sessions (E(2), 18 +/- 0.6 min; placebo, 17 +/- 0.5 min), GH half-life varied directly with dose of GHRP-2 (and, hence, the mean serum GH concentration) in both the E(2) and placebo sessions (test of zero sl…
    2 context sentences
    Summary · context
    To examine this postulate, we studied 10 healthy estrogen-withdrawn postmenopausal women, who were given oral placebo or estrogen supplementation [1 mg micronized 17 beta-estradiol (E(2)) twice daily for 7-15 days] in a patient-blinded, prospective, randomized, and within-subject cross-over design.
    Summary · context
    The GH-releasing actions of five semilogarithmically increasing doses of GHRP-2 (absolute range, 0.03-3 microg/kg by bolus iv infusion) vs. saline were evaluated by frequent blood sampling on separate days in the morning while fasting.

    In this study, GHRP-2 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking GHRP-2.

  5. 07HumanNot a test of GHRP-2 aloneRandomized controlled trialActivity measurement

    In healthy postmenopausal women, estradiol did not alter the latency of the GH secretory burst peak after GHRP‑2.

    In plain wordsIn healthy postmenopausal women, estradiol did not change how quickly growth hormone peaked after GHRP‑2.

    Peptide
    GHRP-2
    Outcome
    No significant changeLatency of GH burst peak with estradiol
    Study

    n = 10

    Comparator
    Placebo
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones

    Source sentences

    Summary
    The deconvolved GH secretory burst peaked within 8-13 min of the bolus iv injection of GHRP-2, and this latency was not altered by E(2).
    2 context sentences
    Summary · context
    To examine this postulate, we studied 10 healthy estrogen-withdrawn postmenopausal women, who were given oral placebo or estrogen supplementation [1 mg micronized 17 beta-estradiol (E(2)) twice daily for 7-15 days] in a patient-blinded, prospective, randomized, and within-subject cross-over design.
    Summary · context
    The GH-releasing actions of five semilogarithmically increasing doses of GHRP-2 (absolute range, 0.03-3 microg/kg by bolus iv infusion) vs. saline were evaluated by frequent blood sampling on separate days in the morning while fasting.

    In this study, GHRP-2 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking GHRP-2.

  6. 08HumanNot a test of GHRP-2 aloneRandomized controlled trialEfficacy outcome

    In healthy postmenopausal women, GHRP‑2 dose and estradiol, but not plasma IGF-I concentration, determined the magnitude of the GH secretory response.

    In plain wordsIn healthy postmenopausal women, GHRP‑2 dose and estradiol, but not blood IGF-I, set how much growth hormone was released.

    Peptide
    GHRP-2
    Outcome
    MixedDeterminants of GH secretory response magnitude
    Study

    n = 10

    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones

    Source sentences

    Summary
    Based on a mixed effects analysis of covariance model, GHRP-2 dose and E(2), but not the plasma insulin-like growth factor I concentration, determined the magnitude of the GH secretory response (P < 0.001).
    2 context sentences
    Summary · context
    To examine this postulate, we studied 10 healthy estrogen-withdrawn postmenopausal women, who were given oral placebo or estrogen supplementation [1 mg micronized 17 beta-estradiol (E(2)) twice daily for 7-15 days] in a patient-blinded, prospective, randomized, and within-subject cross-over design.
    Summary · context
    The GH-releasing actions of five semilogarithmically increasing doses of GHRP-2 (absolute range, 0.03-3 microg/kg by bolus iv infusion) vs. saline were evaluated by frequent blood sampling on separate days in the morning while fasting.

    In this study, GHRP-2 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking GHRP-2.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    13 Oct 2026, 21:44 UTC

    Study results updated

  2. Version 1

    13 Oct 2026, 16:31 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.